ARCUTIS BIOTHERAPEUTICS INC (ARQT)
Health Care · biopharmaceuticals · NASDAQ
Arcutis Biotherapeutics is a commercial-stage dermatology company delivering innovative, targeted treatments for immune-mediated skin conditions.
What ARCUTIS BIOTHERAPEUTICS INC does
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological conditions. The company's portfolio addresses significant unmet needs in inflammatory skin diseases. Its lead commercial activities center on therapies for conditions such as plaque psoriasis and seborrheic dermatitis.
Themes: dermatology, plaque psoriasis treatments, seborrheic dermatitis treatments, inflammatory skin disease therapeutics
Fundamentals
- Price$24.78 as of 2026-08-24 close
- Market cap$3.1B as of 2026-08-24
- 1-year return+55.0% 2025-08-22 close $15.99 → 2026-08-24 close $24.78
- P/E115.52 as of 2026-08-24
- Net margin+6.2% as of 2026-08-24
- Gross margin+91.1% as of 2026-08-24
- ROE+15.0% as of 2026-08-24
- Debt / equity0.49 as of 2026-08-24
- Revenue growth (YoY)+76.1% as of 2026-08-24
- Revenue CAGR (3y)+367.3% SEC XBRL
- Beta1.18 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How ARQT compares in its sector
- price-to-earnings ratiotop 10% 193 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ARQT is not currently in any published Top 10 list. Its scores are below.
Long-term score
46.7 #1016 of 1,605 scored · #119 of 195 in Health Care
Growth 99th (3-year revenue CAGR 367.3%, revenue growth year over year 76.1%) and financial health 45th (debt to equity 0.5, free cash flow margin 8.4%); weakest is valuation (10th, price to earnings 115.5, price to book 14.1).
Short-term score
51.9 #568 of 1,698 scored · #119 of 236 in Health Care
Catalysts 75th: open-market insider buys in 90 days 30, analysts have raised their average price target by 0.7% since the prior reading; volume and participation 63rd: it gapped 7.7% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is trend 28th: it is trading 7.2% below its 50-day average, the short-term trend line.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How ARCUTIS BIOTHERAPEUTICS INC looks technically
ARCUTIS BIOTHERAPEUTICS INC (ARQT) is trading 3.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 15 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-06-12, breaking below its recent trading range. It is 22.0% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 3.4% below its 200-day average, the long-term trend line — a long-term downtrend | -3.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.72 | $26.72 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $25.64 | $25.64 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 15 trading days ago — a "golden cross", a bullish long-term signal | 15 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 17.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 39.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($24.49 to $29.24) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 6.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $31.77 | $31.77 |
|---|---|---|
| From the 52-week high | it is 22.0% below its 52-week high (its highest price of the past year) | -22.0% |
| Above the 52-week low | it is 64.1% above its 52-week low (its lowest price of the past year) | +64.1% |
| Below the 52-week high | it is 22.0% below its highest point of the past year | 22.0% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-12, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $40.88 (set on 2020-03-20) | $40.88 |
| Given back of the 52-week move | over the past year its closes ranged ($15.32 to $31.20), and it has given back roughly a third of its rise from last year’s low — 40% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.88 to $21.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 40.4% |
| From the all-time high | it is 39.4% below its all-time high | -39.4% |
| Nearest price level | it is trading 1.1% below a resistance level at $25.04 — a price it turned at three times since 2026-01-20, most recently on 2026-08-10. Since 2024-08-26 it has 14 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.1% |
| All-time low | its lowest closing price on record is $1.76 (set on 2023-12-01) | $1.76 |
| Above the all-time low | it is 1308.0% above its all-time low | +1,308% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.14 between its high and its low — about 4.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.14 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $24.43 and $28.19 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $24.43 – $26.31 – $28.19 |
| Typical daily range (% of price) | its price moves about 4.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.6% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges below its 200-day average price (3.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.72× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.7% since the prior reading | +0.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 1.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.1% |
|---|---|---|
| Open gap | it gapped 7.7% above the previous close 50 sessions ago and has not traded back through the level it left behind at 21.54 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +7.7% |
| Gap filled | a 7.8% gap up opened on 2026-08-06 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 4 sessions in a row, a -6.63% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 4 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 12.7 percentage points (the stock lost 9.4% while the market gained 3.3%) | -12.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.4 percentage points (the stock gained 18.8% while the market gained 2.4%) | +16.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 19.2 percentage points (the stock lost 8.2% while the market gained 11.1%) | -19.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 36.7 percentage points (the stock gained 55.0% while the market gained 18.3%) | +36.7% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 8.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $24.92 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -0.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $25.93 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | -4.4% |
Price levels it has turned at before
ARQT last closed at $24.78 on 2026-08-24. Since 2024-08-26 it has turned at 14 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $25.04 | Resistance | 1.1% above the last close | turned there three times · 2026-01-20 to 2026-08-10 |
| $24.38 | Support | 1.6% below the last close | turned there twice · 2026-02-02 to 2026-05-06 |
| $25.50 | Resistance | 2.9% above the last close | turned there twice · 2026-03-10 to 2026-04-14 |
| $27.08 | Resistance | 9.3% above the last close | turned there twice · 2025-10-30 to 2026-01-22 |
| $22.07 | Support | 10.9% below the last close | turned there four times · 2025-10-16 to 2026-05-27 |
| $17.73 | Support | 28.5% below the last close | turned there twice · 2025-03-17 to 2025-03-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$36.88 range $34.00 – $40.00; median $37.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ARQT
- Consensus EPS estimate$0.1583 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["dependence on continued successful commercialization of current products","significant capital requirements and history of accumulated deficits","intense competition in the dermatology and immunology markets"]
What changed in the latest 10-Q
AI-assisted comparison of ARQT's 10-Q filed 2026-05-06 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- November 2025: sNDA was accepted for filing by FDA for ZORYVE cream 0.3% for plaque psoriasis in children down to age 2, with PDUFA target action date of June 29, 2026 (newer filing, 2026-05-06)
- February 2026: Health Canada accepted SNDS for ZORYVE cream 0.3% for individuals down to 2 years of age (newer filing, 2026-05-06)
- Health Canada approval of ZORYVE foam for plaque psoriasis of scalp and body in October 2025 with commercial launch in November 2025 (newer filing, 2026-05-06)
- Completion of enrollment in MUSE trial for ZORYVE foam in children with plaque psoriasis of scalp and body ages 2-11 (newer filing, 2026-05-06)
- FDA approval for ZORYVE cream 0.05% in October 2025 (newer filing, 2026-05-06)
- Health Canada acceptance of SNDS for ZORYVE cream 0.05% in October 2025 (newer filing, 2026-05-06)
- February 2026: Announcement of positive topline data for INTEGUMENT-INFANT Phase 2 study (newer filing, 2026-05-06)
- April 2026: Submission of sNDA to FDA for ZORYVE cream 0.05% for infants down to 3 months of age (newer filing, 2026-05-06)
- Effective January 23, 2026: Mutual termination of Kowa promotion agreement with cessation of sales and no further payment obligations (newer filing, 2026-05-06)
- Removed:
- Reference to audited financial statements for year ended December 31, 2024 (older filing, 2025-10-28) replaced with December 31, 2025 (newer filing, 2026-05-06)
- Phrase 'and plan to commercially launch in October 2025' regarding ZORYVE cream 0.05% (older filing, 2025-10-28) removed as it is now completed
- Paragraph describing development of ARQ-255 and ARQ-234 programs (older filing, 2025-10-28) not present in newer filing
- Disclosure of net losses of $33.5 million and $129.3 million for nine months ended September 30, 2025 and 2024 (older filing, 2025-10-28) not present in excerpt of newer filing
- Reworded:
- Changed 'and to use' to 'to use' in strategy description (minor punctuation/grammar change, newer filing 2026-05-06)
- Changed 'address the major shortcomings' to 'address major shortcomings' (removed definite article, newer filing 2026-05-06)
- Changed 'maximizing our probability of technical success and financial resources' to 'maximizing our probability of technical success and efficient use of financial resources' (newer filing 2026-05-06)
- Changed 'plaque psoriasis, including psoriasis in the intertriginous areas (e.g. groin or axillae)' to include space after 'e.g.,' (newer filing 2026-05-06)
- Changed 'for once-daily treatment' to 'for once-daily topical treatment' (added 'topical', newer filing 2026-05-06)
- Changed 'In September 2025, we submitted a supplemental New Drug Application' to 'In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA' (newer filing 2026-05-06)
- Changed 'we had our first commercial launch' to 'we achieved our first commercial launch' (newer filing 2026-05-06)
- Changed 'individuals 12 years or age' to 'individuals 12 years of age' (grammar correction, newer filing 2026-05-06)
- Changed 'ZORYVE ® (roflumilast) topical foam 0.3% (ZORYVE foam)' to 'ZORYVE foam 0.3% (ZORYVE foam)' (simplified naming, newer filing 2026-05-06)
- Changed 'is the first drug approved' to 'was the first drug approved' (tense change, newer filing 2026-05-06)
- Changed 'and was approved by Health Canada in October 2024 and became commercially available in Canada in December 2024' to 'and in Canada in November 2024' (different timing, newer filing 2026-05-06)
- Changed 'ages 12 and older' to 'aged 12 and older' (grammar change, newer filing 2026-05-06)
- Changed description of ZORYVE cream 0.15% approval to reflect actual launch status (newer filing 2026-05-06)
- Changed 'for treatment of' to 'for the topical treatment of' (added 'the' and 'topical', newer filing 2026-05-06)
- Changed 'of age and older' to 'and older' (removed redundant 'of age', newer filing 2026-05-06)
- Changed 'In June 2025, we initiated INTEGUMENT-INFANT' to 'In February 2026, we announced positive topline data for INTEGUMENT-INFANT' with description of completed trial rather than initiated (newer filing 2026-05-06)
- Changed 'potentially could serve as' to 'has been completed with positive results that serve as' (newer filing 2026-05-06)
- Changed 'co-promotion agreement with Kowa Pharmaceuticals, Inc.' to 'promotion agreement with Kowa Pharmaceuticals America, Inc.' (newer filing 2026-05-06)
- Changed 'will receive a commission' to 'received a commission' (past tense, reflecting termination, newer filing 2026-05-06)
- Notes:
- The older filing excerpt ends mid-sentence regarding net losses and accumulated deficit, limiting comparison of complete MD&A sections
- The newer filing excerpt does not include the full closing sections of the older filing regarding ARQ-255 and ARQ-234 programs, making complete comparison impossible
Risk Factors
- Reworded:
- In Balance Sheet header: changed from 'share and par value' in older filing to no such parenthetical in newer filing (2026-05-06 vs 2025-10-28)
- In Balance Sheet header: older filing showed 'September 30, 2025' and 'December 31, 2024' as comparison dates; newer filing shows 'March 31, 2026' and 'December 31, 2025'
- In Statement of Operations header: older filing titled it 'Statements of Operations and Comprehensive Income (Loss)'; newer filing titled it 'Statements of Operations and Comprehensive Loss'
- In Statement of Operations: older filing included 'Other income, net' as a line item separate from interest expense; newer filing split this into 'Interest income' and 'Other income (expense), net' as separate line items
- In Statement of Changes in Stockholders' Equity header: older filing referenced 'Accumulated Other Comprehensive Income (Loss)'; newer filing referenced 'Accumulated Other Comprehensive Loss'
- In Cash Flow Statement: older filing header stated 'Nine Months Ended September 30'; newer filing header stated 'Three Months Ended March 31'
- Notes:
- The two filings compare different fiscal periods (Q1 2026 vs Q3 2025) and different year-end dates, making direct financial comparison not applicable to this assessment
- The document excerpts are truncated and do not include complete Risk Factors sections, limiting ability to assess all changes in that section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 11 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 7 sells ($735877) — 4 selling insiders
- Last 90 days0 buys · 11 sells ($1M) — 5 selling insiders
- Last 180 days0 buys · 19 sells ($2M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-19. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ARQT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 3 matched disclosures for ARQT from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ARQT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 16,314,549
- Reported value $384,370,788
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ARQT had 12,686,384 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ARQT had 10.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.74 days to cover at the same settlement.
- Reported short interest (shares) 12,686,384
- Short interest (% of shares outstanding) 10.1%
- Prior settlement (shares) 13,561,565
- Reported change -6.45%
- Days to cover (reported) 10.74
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Incyte (INCY)
- Bristol Myers Squibb (BMY)
- Galderma (GDER)
- AbbVie (ABBV)
- Amgen (AMGN)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ARQT vs…
ARQT ranks in…
Frequently asked questions
What does ARCUTIS BIOTHERAPEUTICS INC (ARQT) do?
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological conditions. The company's portfolio addresses significant unmet needs in inflammatory skin diseases. Its lead commercial activities center on therapies for conditions such as plaque psoriasis and seborrheic dermatitis.
What sector is ARCUTIS BIOTHERAPEUTICS INC (ARQT) in?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) is classified in the Health Care sector. Its industry is biopharmaceuticals. It trades on NASDAQ.
Who are ARCUTIS BIOTHERAPEUTICS INC's (ARQT) competitors?
Notable peers of ARCUTIS BIOTHERAPEUTICS INC (ARQT) include Incyte, Bristol Myers Squibb, Galderma, AbbVie and Amgen. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ARQT?
Yes — we hold 3 matched STOCK Act disclosures for ARQT from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ARCUTIS BIOTHERAPEUTICS INC (ARQT) overbought or oversold right now?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ARQT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.